Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

IMMUNOLOGY is a premier journal published by Wiley that has been at the forefront of the field since its inception in 1958. With an impressive impact factor and classified in the Q1 quartile for both Immunology and Allergy as of 2023, this journal is highly regarded among researchers and professionals alike. It ranks 36th out of 233 in the Medicine/Immunology and Allergy category, and 40th out of 236 in the Immunology and Microbiology segment on Scopus, placing it firmly within the top percentile of its field. The journal is dedicated to publishing high-quality research that advances our understanding of immunological processes, bridging basic science with clinical applications. Although it does not operate under an open-access model, it offers conventional access options that remain integral to the dissemination of vital immunological research. With its broad scope and commitment to scholarly excellence, IMMUNOLOGY continues to serve as an essential resource for those seeking the latest advancements in immunology, fostering innovation and collaboration among scientists globally.

CURRENT OPINION IN IMMUNOLOGY is a prestigious journal dedicated to the dynamic field of immunology, published by CURRENT BIOLOGY LTD in the United Kingdom. With an ISSN of 0952-7915 and an E-ISSN of 1879-0372, this journal has been a cornerstone of scholarly communication since its inception in 1988 and continues to disseminate cutting-edge research and reviews aimed at advancing our understanding of immune responses. Holding a remarkable Q1 ranking in both Immunology and Allergy categories for 2023, it ranks impressively within the top percentiles in its field, securing 27th233 in Immunology and Allergy and 31st out of 236 in Immunology and Microbiology. Emphasizing high-impact research, the journal provides researchers, professionals, and students with valuable insights into emerging trends and critical developments. As a vital resource in immunological research, it serves as a platform for disseminating innovative findings, fostering collaboration, and enhancing scholarly exchange in a rapidly evolving scientific landscape.

IMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

Scandinavian Journal of Immunology is a prestigious peer-reviewed journal published by Wiley, focused on the evolving field of immunology and its interdisciplinary ties with medicine. Since its inception in 1972, this journal has cultivated a rich repository of knowledge, showcasing innovative research and reviews that contribute to the understanding of immune system functions, disorders, and therapeutic interventions. With an impressive impact factor reflecting a Q2 ranking in Immunology and a top-tier Q1 status in miscellaneous Medicine categories for 2023, it is recognized for its high-quality scholarly output, positioning it among the leading journals in the field. Additionally, its Scopus ranking of #84 out of 236 in Immunology underscores its significance and relevance to both emerging and established researchers. Although it does not currently offer open access options, the journal’s expansive reach and rigorous publication standards make it an essential platform for disseminating impactful research to the global scientific community. The journal invites submissions that explore the complexities of the immune system, aiming to bridge clinical and basic science for a comprehensive understanding of immunological phenomena.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.